Author/Authors :
Ueno، نويسنده , , Yuko and Enomoto، نويسنده , , Takayuki and Otsuki، نويسنده , , Yoshiro and Sugita، نويسنده , , Nagatoshi and Nakashima، نويسنده , , Ryuichi and Yoshino، نويسنده , , Kiyoshi and Kuragaki، نويسنده , , Chie and Ueda، نويسنده , , Yutaka and Aki، نويسنده , , Tadaatsu and Ikegami، نويسنده , , Hiromasa and Yamazaki، نويسنده , , Masato and Ito، نويسنده , , Kimihiko and Nagamatsu، نويسنده , , Masaaki and Nishizaki، نويسنده , , Takamichi and Asada، نويسنده , , Masahiro and Kameda، نويسنده , , Takashi and Wakimoto، نويسنده , , Akinori and Mizutani، نويسنده , , Takahiro and Yamada، نويسنده , , Takako and Murata، نويسنده , , Yuji، نويسنده ,
Abstract :
The prognostic significance of p53 mutation, microsattelite instability and DNA mismatch protein hMLH1 expression in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin was evaluated. The overall combination chemotherapy response rate and the complete remission rate were significantly higher among patients with mutant p53 tumors than those with wild-type p53 tumors (35/42 (83%) vs. 32/58 (55%); P=0.003 and 18/42 (43%) vs. 16/58 (28%); P=0.03, respectively). This tendency apparently existed in non-serous carcinoma, but not in serous carcinoma. Univariate analysis showed that the risk of death due to disease and risk of progression was significantly lower among patients with p53 mutation (P=0.0357 and 0.0281, respectively). However, the presence of microsattelite instability or loss of hMLH1 expression was not associated with either the clinical response or prognosis. Determining p53 mutational status can be useful in predicting therapeutic response to drugs in ovarian carcinoma, especially in non-serous tumors.
Keywords :
p53 , Prognosis , carboplatin , Ovarian Carcinoma , Paclitaxel
